DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Putrescine is an investigational drug.
There have been 6 clinical trials for Putrescine. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Colorectal Neoplasms, and Subarachnoid Hemorrhage. The leading clinical trial sponsors are National Cancer Institute (NCI), University Hospital, Bordeaux, and University of Zagreb.
There are three US patents protecting this investigational drug and twenty-seven international patents.
Recent Clinical Trials for Putrescine
|Effect of Probiotic Lozenges on Halitosis in Patients With Chronic Periodontitis||BioGaia AB||Phase 4|
|Effect of Probiotic Lozenges on Halitosis in Patients With Chronic Periodontitis||University of Zagreb||Phase 4|
|Feasibility Study on Stem Cells Sensitivity Assay||Associazione Oncologia Traslazionale||Phase 2|
Top disease conditions for Putrescine
Top clinical trial sponsors for Putrescine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Putrescine||Start Trial||Method of molding plastic products having chemically bonded protective coatings||Libbey-Owens-Ford Co. (Toledo, OH)||Start Trial|
|Putrescine||Start Trial||Aryloxytriazine-capped polyphenylene ethers and method for their preparation||General Electric Company (Schenectady, NY)||Start Trial|
|Putrescine||Start Trial||Method for producing polyurethanes from poly-(hydroxyalkyl urethanes)||Medtronic, Inc. (Minneapolis, MN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|